IDH1 and central nervous system cancer: Subsequent studies have shown that IDH2 mutations are also enriched in WHO grade II/III gliomas, albeit less frequently, and that IDH1/2 mutations occur in a mutually exclusive manner (Hartmann et al., 2009).